Stantec and Jacobs Secure Key Melbourne Water Infrastructure Project
Money

Stantec and Jacobs Secure Key Melbourne Water Infrastructure Project

authorBy Bola Sokunbi
DateJun 13, 2026
Read Time2 min

Stantec Inc. and Jacobs Solutions have recently secured a major contract to implement Greater Western Water's five-year infrastructure plan in Melbourne, Australia. This critical program is designed to enhance water and sewer infrastructure, addressing the demands of a rapidly growing population in Melbourne's western region, which is projected to more than double by 2050.

The joint venture will provide a full spectrum of engineering and advisory services. These include comprehensive system design, development of treatment facilities, water resource assessments, and thorough environmental impact analyses. Furthermore, the partnership will extend to offering construction support and developing new operational standards, ensuring the longevity and efficiency of the new infrastructure. Both companies emphasize their commitment to improving the reliability and sustainability of the infrastructure, while also proactively adapting to environmental and demographic challenges. The program also incorporates social procurement initiatives, fostering partnerships with Indigenous-owned enterprises and investing in local workforce training to deliver wider community and economic advantages.

Stantec Inc. is renowned for its global expertise in engineering, architecture, environmental consulting, and design across various sectors, including extensive experience in water infrastructure management, ranging from potable water systems to wastewater treatment, flood control, and water resource management projects worldwide. Through this project, Stantec and Jacobs are not only constructing vital infrastructure but also building a foundation for a more resilient and equitable future for Melbourne's growing communities.

More Articles
Money
US-Iran Peace Agreement: Hopes and Hurdles
Pakistan's Prime Minister Shehbaz Sharif announced the imminent finalization of a peace agreement between the US and Iran within 24 hours, aiming to resolve over three months of conflict that has severely impacted global energy markets. The potential deal seeks to address key contentious issues such as maritime traffic in the Strait of Hormuz, Iran's nuclear program, and the unfreezing of Iranian assets, despite ongoing disagreements and recent military skirmishes.
By Ramit SethiJun 13, 2026
Money
Vertiv Holdings Co: A Top Investment for June's Market
Vertiv Holdings Co (VRT) has been identified as a leading stock pick for June, following a decision by its board of directors on June 3 to approve a quarterly cash dividend of $0.0625. This dividend, payable on June 25, 2026, to shareholders of record by June 15, 2026, highlights the company's consistent growth and strong financial health.
By T. Harv EkerJun 13, 2026
Money
Ameriprise Financial: A Top Choice Among Undervalued Quality Stocks
Ameriprise Financial (AMP) is recognized as one of the most undervalued quality stocks. The recent integration of Pattern Wealth, a private wealth advisory practice, into Ameriprise's network underscores the company's commitment to enhancing client experience through advanced tools, technology, and a strong brand presence. This move is set to broaden service offerings, particularly in retirement planning and investment advice, reinforcing Ameriprise's market position.
By Bola SokunbiJun 13, 2026
Money
Willis Towers Watson Enhances International Property Facility with Expanded Capacity
Willis Towers Watson (WTW) has significantly broadened its international property facility, boosting the available follow capacity to a substantial $60 million per placement. This expansion integrates a wider array of Lloyd's syndicates, fostering competitive quotes across primary and excess insurance layers. The enhanced facility leverages WTW's Neuron digital trading platform, extending its reach across diverse global regions and numerous industry sectors.
By Vicki RobinJun 13, 2026
Money
Corvus Pharmaceuticals: A Promising Investment Opportunity?
Corvus Pharmaceuticals, a biopharmaceutical company, is drawing significant attention for its lead product candidate, soquelitinib. This article summarizes a bullish outlook on CRVS, highlighting its potential as a high-conviction immunology and oncology catalyst. The company's innovative ITK inhibitor aims to redefine T-cell biology, offering a novel approach to treating conditions like atopic dermatitis. With positive early-phase data and a robust financial position, Corvus Pharmaceuticals is poised for potential growth and could be an attractive acquisition target.
By Dave RamseyJun 13, 2026